Abraxis BioScience Inc., long rumored to be a take-out target, particularly after the January departure of CEO Lonnie Moulder, is being acquired by Celgene Corp. in a $2.9 billion cash and stock deal that gives the big biotech rights to Abraxis' nanoparticle albumin bound-based drug pipeline, including star cancer drug Abraxane. (BioWorld Today)